

# Nova Eye Medical Representative Appointed to American Glaucoma Society (AGS) Foundation Advisory Board

## **Highlights**

- President of USA subsidiary, Nova Eye, Inc. has been appointed to the influential AGS Foundation Advisory Board
- Mr. Joe Bankovich appointed as an Industry Representative
- AGS provides a platform to collaborate and guide the approval of new glaucoma diagnostic technologies and surgical devices

Nova Eye Medical Limited (ASX: EYE) (**Nova Eye Medical** or the **Company**), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today is pleased to announce that Mr. Joe Bankovich, President of Nova Eye, Inc, the USA operating subsidiary of Nova Eye Medical, has been appointed as an Industry Representative to the American Glaucoma Society (**AGS**) Foundation Advisory Board.

Established in 2011 and comprising over 1500 members, the American Glaucoma Society Foundation runs a number of programs to support glaucoma research and education. This includes programs designed to accelerate the advancement of glaucoma science and its translation into clinically important applications. One of the most influential subspecialty societies in the USA, the American Glaucoma Society Foundation also provides a platform for physicians, researchers and the USA Food and Drug Administration (FDA) to collaborate in the development of the regulatory science that guides the approval of new glaucoma diagnostic technologies and surgical devices – and thus functions as a critical link between industry and the regulatory arena.

## **Nova Eye Medical Managing Director, Tom Spurling, commented:**

"The American Glaucoma Society Foundation has become one of American ophthalmology's premier subspecialty societies and we are pleased that Joe's expertise has been recognised by the Foundation.

We believe Joe's extensive understanding of ophthalmology, new technology commercialisation and strategy, as well as significant industry experience, qualify him to serve on the Foundation's Advisory Board."

### **About the American Glaucoma Society Foundation**

The American Glaucoma Society is comprised of Glaucoma Specialists dedicated to sharing clinical and scientific information for the benefit of patients, colleagues, fellows and residents. Together with other health care organizations, the AGS serves as an important patient advocacy force to promote glaucoma awareness among policy makers and the general population.

For additional information about the American Glaucoma Society Foundation, please visit: https://www.americanglaucomasociety.net

This release dated 31 March 2022 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.

#### - ENDS -

Company
Tom Spurling
Managing Director
+61 417 818 658
tspurling@nova-eye.com

Company
Kate Hunt
Head of Marketing
+61 404 080 679
khunt@nova-eye.com

Investors
Mark Flynn
Investor Relations
+61 416 068 733
mflynn@nova-eye.com

## **ABOUT NOVA EYE MEDICAL**

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of advanced and complex glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com